Study explores the potential to repurpose neuroactive drugs, originally approved for neurological disorders, for the ...

Relay Therapeutics has up to 3.3 years cash runway, which, I believe, is sufficient to cover the RLY-2608's upcoming ...

Relay Therapeutics (NASDAQ:RLAY) stock rallied 41% in morning trading Monday after the drug developer reported positive ...

根据在FGFR2 融合+ ICC 细胞中抑制 FGFR后观察到的代谢可塑性，我们接下来探索了针对新出现的代谢弱点提高疗效的可能性。为此，我们测试了联合抑制FGFR和线粒体氧化代谢的效果。ONC212是一种对线粒体蛋白质量控制至关重要的ClpP蛋白酶激动剂，ONC212增强了FGFRi 在ICC13-7 和ICC21 细胞中的疗效，还研究了降低葡萄糖条件对这些反应的影响发，现，ONC212与 ...

Relay Therapeutics (RLAY) has received a new Buy rating, initiated by Goldman Sachs analyst, Salveen Richter. Salveen Richter has given his Buy ...

Relay Therapeutics Inc. (NASDAQ:RLAY) shared interim data for RLY-2608 from ReDiscover study, an ongoing first-in-human study ...

(C) Novel signaling cascade. In Purkinje cells of the cerebellum, Fgf10 binds to Fgfr2, initiating a cascade in which Pkrca leads to the activation of Mapk1, which recruits Runx2 for further ...

艾德生物 9月5日午间公告，公司自主研发的FGFR2基因断裂检测试剂盒（荧光原位杂交法），于近日获得日本厚生劳动省批准上市。该基因检测试剂盒适用于检测肿瘤组织中FGFR2基因融合或重排（用于帮助确定胆管癌患者是否适合服用Tasurgratinib）。

1.艾德生物：公司自主研发的FGFR2基因断裂检测试剂盒（荧光原位杂交法）近日获得日本厚生劳动省批准上市。该产品预期用途为检测肿瘤组织中FGFR2基因融合或重排（用于帮助确定胆管癌患者是否适合服用Tasurgratinib）。该产品的获批，进一步丰富了公司肿瘤伴随诊断产品线。 2.金沃股份：公司筹划实施限制性股票激励计划，拟授予激励对象权益总计不超过330万股，占公司目前股本总额7680.19万股 ...

The FDA suggested that the company first file a new drug application (NDA) in cholangiocarcinoma, followed by a tumor-agnostic supplemental NDA for FGFR2 fusions with data from more patients and ...